Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16943524rdf:typepubmed:Citationlld:pubmed
pubmed-article:16943524lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0040083lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0671970lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:16943524lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:16943524pubmed:issue25lld:pubmed
pubmed-article:16943524pubmed:dateCreated2006-8-31lld:pubmed
pubmed-article:16943524pubmed:abstractTextTo evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity.lld:pubmed
pubmed-article:16943524pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:languageenglld:pubmed
pubmed-article:16943524pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:citationSubsetIMlld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16943524pubmed:statusMEDLINElld:pubmed
pubmed-article:16943524pubmed:monthSeplld:pubmed
pubmed-article:16943524pubmed:issn1527-7755lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:DiasioRobert...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:KovatichAlber...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:MeropolNeal...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:MitchellEdith...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:SchwartingRol...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:GoldPhilip...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:AndriaMichael...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:DhamiMandeepMlld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:GodfreyThomas...lld:pubmed
pubmed-article:16943524pubmed:authorpubmed-author:LundKirk AKAlld:pubmed
pubmed-article:16943524pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16943524pubmed:day1lld:pubmed
pubmed-article:16943524pubmed:volume24lld:pubmed
pubmed-article:16943524pubmed:ownerNLMlld:pubmed
pubmed-article:16943524pubmed:authorsCompleteYlld:pubmed
pubmed-article:16943524pubmed:pagination4069-77lld:pubmed
pubmed-article:16943524pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:meshHeadingpubmed-meshheading:16943524...lld:pubmed
pubmed-article:16943524pubmed:year2006lld:pubmed
pubmed-article:16943524pubmed:articleTitleThymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.lld:pubmed
pubmed-article:16943524pubmed:affiliationFox Chase Cancer Center, Philadelphia, PA 19111, USA. Neal.Meropol@fccc.edulld:pubmed
pubmed-article:16943524pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16943524pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:16943524pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16943524pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16943524lld:pubmed